

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/597378-Conf. #1083
				Filing Date	July 21, 2006
				First Named Inventor	Sung Lan HSIA <i>et al.</i>
				Art Unit	1651
				Examiner Name	Thane E. Underdahl
Sheet	1	of	3	Attorney Docket Number	117732-01601

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US5,527,789	6/18/1996	Nyce	
	A2	US5,605,930	2/25/1997	Samid	
	A3	US6,093,706	7/25/2000	Zeligs	
	A4	US6,348,506	2/19/2002	Sneed	
	A5	US6,441,050	8/27/2002	Chopra	
	A6	US6,465,517	10/15/2002	Van Der Zee	
	A7	US6,469,061	10/22/2002	Flesher	
	A8	US6,569,463	5/27/2003	Patel	
	A9	US6,682,763	1/27/2004	Kuno	
	A10	US6,726,924	4/27/2004	Keller	
	A11	US6,866,864	3/15/2005	Mousa	
	A12	US6,923,988	8/2/2005	Patel	
	A13	US7,005,274	2/28/2006	Terkeltaub	
	A14	US7,060,733	6/13/2006	Pandol	
	A15	US7,456,161	11/25/2008	Nyce	
	A16	US7,635,722	12/22/2009	Bachynsky	
	A17	US7,776,894	8/17/2010	Ronai	
	A18	US7,824,673	11/2/2010	Wegman	
	A19	US7,858,659	12/28/2010	Hoffman	
	A20	US7,879,823	2/11/2011	Seiberg	
	A21	US20020058712	5/16/2002	Sneed	
	A22	US20020136711	9/26/2002	Cochran	
	A23	US20020164317	11/7/2002	Gorsek	
	A24	US20020198177	12/26/2002	Horrobin	
	A25	US20030103954	6/5/2003	Rosenbloom	
	A26	US20030105027	6/5/2003	Rosenbloom	
	A27	US20030118525	6/26/2003	Grigg	
	A28	US20030118536	6/26/2003	Rosenbloom	
	A29	US20030207834	11/6/2003	Dale	
	A30	US20030212114	11/13/2003	Sato	
	A31	US20040063661	4/1/2004	Linnane	
	A32	US20040082522	4/29/2004	Nyce	
	A33	US20040115181	6/17/2004	Fujii	
	A34	US20040253323	12/16/2004	Giles	
	A35	US20050019268	1/27/2005	Enzmann	
	A36	US20050025756	2/3/2005	Erwin	
	A37	US20050026848	2/3/2005	Robinson	
	A38	US20050026850	2/3/2005	Robinson	
	A39	US20050070610	3/31/2005	Fujii	
	A40	US20050226947	10/13/2005	Kern	
	A41	US20050239721	10/27/2005	Rosenbloom	
	A42*	US20050288333	12/29/2005	Kern	
	A43	US20060052438	3/9/2006	Ho	
	A45	US20060062755	3/23/2006	Woodward	
	A46	US20060110415	5/25/2006	Gupta	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/597378-Conf. #1083
				Filing Date	July 21, 2006
				First Named Inventor	Sung Lan HSIA <i>et al.</i>
				Art Unit	1651
Examiner Name	Thane E. Underdahl				
Sheet	2	of	3	Attorney Docket Number	117732-01601

A47	US20060120997	6/8/2006	Lipton	
A48	US20060205771	9/14/2006	Noble	
A49	US20070021360	1/25/2007	Nyce	
A50	US20070026072	2/1/2007	Olsen	
A51	US20070129428	6/7/2007	Richelle	
A52	US20070149618	6/28/2007	Sanchez	
A53	US20070225255	9/27/2007	Frolich	
A54	US20080020018	1/24/2008	Moodley	
A55	US20080260878	10/23/2008	Harano	
A56	US20080287541	11/20/2008	Hoffman	
A57	US20090010917	1/8/2009	Rosenblum	
A58	US20090137556	5/28/2009	Bonnichsen	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	Japanese Laid - Open Patent Publication No S57-75916	5/12/1982	Nippon Chemipharm Co. Ltd.		
	B2	Japanese National Phase Laid - Open Publication No. 2001-514209	9/11/2001	Biozone Laboratories		
	B3	WO199911242	03/11/1999	Keller		
	B4	WO2002062329	8/15/2002	Borowy-Borowski		
	B5	WO2006017494	2/16/2006	Mazzio		
	B6	WO2006063402	6/22/2006	Stewart		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/597378-Conf. #1083
				Filing Date	July 21, 2006
				First Named Inventor	Sung Lan HSIA <i>et al.</i>
				Art Unit	1651
				Examiner Name	Thane E. Underdahl
Sheet	3	of	3	Attorney Docket Number	117732-01601

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C1	Conklin KA (2004) Cancer Chemotherapy and Antioxidants, <i>J.Nutr.</i> 134:3201S-3204S.		
	C2	Crane FL (2000) New Functions for Coenzyme Q10, <i>Protoplasm</i> , 213:127-133.		
	C3	de Oliveria (1998) A Nutritious Cocktail for the Treatment of Melanoma: A Case Report, <i>Journal of Orthomolecular Medicine</i> , 13(3)		
	C4	Hodges S (1999) CoEnzyme Q10: Could It Have a Role in Cancer Management <i>Biofactors</i> , 134:365-370.		
	C5	Kawase I (1978) Enhancing Effect of Coenzyme Q10 on Immunorestitution with Mycobacterium Bovia BCG in Tumor-Bearing Mice <i>Gann</i> , 69(4):493-497.		
	C6	Li, GJ (1987) Protective Effect of Coenzyme Q10 against the Adverse Reaction of Mytomycin G in Mouse Liver <i>Acta Histochemica et Cytochemica</i> 1087, 20(4):455-467.		
	C7	Larsson O (1994) Effets of Isoprenoids on Growth of Normal Human Mammary Epithelial Cells and Breast Cancer Cells in vitro. <i>Anticancer Research</i> 14:123-128		
	C8	Palan PR (2003) Plasma Concentrations of Coenzyme Q10 and Tocopherols in Cervical Intrepthelial Neoplasia and Cervical Cancer. <i>Eur. J. Cancer Prev.</i> 12:321-326		
	C9	Roffe (2004) Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review. <i>J. Clin. Oncol.</i> 22:4418-24.		
	C10	Shekelle P (2003) Effect of the Supplemental Use of Antioxidants Vitamin C, Vitamin E, Coenzyme Q10 for the Prevention and Treatment of Cancer. <i>Evid. Rep. Technol. Assess.</i> 75:1-3		
	C11	Shimizu T (2003) Paclitaxel Pirarubicin Weekly. <i>Japan J. Cancer and Chemotherapy</i> 30:105-109		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.